Macular‐type cutaneous adverse reaction due to atezolizumab and pembrolizumab

Abstract

Anti‐PD‐1/PD‐L1 targeted therapy is widely used for the treatment of various intractable malignancies and develops the therapeutic option in the frontier fields of oncology treatment. On the contrary, these immune checkpoint therapies sometimes develop undesirable adverse reaction as the results of activation of immune reaction to various organs. Herein, we report a case of cutaneous adverse reactions during PD‐1/PD‐L1 targeted treatment in both atezolizumab and pembrolizumab in a patient with lung cancer.

A subcutaneous abscess following anti‐programmed cell death 1/programmed death‐ligand 1 antibody treatment for lung cancer

“…A 68‐year‐old man had undergone a surgical appendectomy for appendicitis 20 years ago. He had intractable distant metastasis of lung primary cancer and received pembrolizumab and atezolizumab experiencing cutaneous adverse reaction as a previously reported case 3 . Because of a cutaneous adverse reaction to pembrolizumab and atezolizumab, systemic therapy was discontinued.…”

“…He had intractable distant metastasis of lung primary cancer and received pembrolizumab and atezolizumab experiencing cutaneous adverse reaction as a previously reported case. 3 Because of a cutaneous adverse reaction to pembrolizumab and atezolizumab, systemic therapy was discontinued. However, he recognized a subcutaneous lump and pain located in the previously received appendectomy site 1 month after the administration of pembrolizumab and gradually developed into a swelling subcutaneous mass (Figure 1A).…”